RxDoctor Payments Data

Kimberly Hamilton

Family · Morehead, KYNPI 1114206174

Payments from drug & device makers

$2,383in general payments, 2019–2025

Across 117 payments — averaging $20.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$409
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$351
  • Novartis$188
  • Harmony Biosciences LLC$179
  • Boehringer Ingelheim$161
  • Jazz Pharmaceuticals Inc.$112
  • plus $983 from 19 others

What the payments were for

  • Food & beverage$2,28396%
  • Education$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,383 in reported general payments places this provider in the 80th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$26,984
Medicare patients
193
Services billed
366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban74$61,615
XareltoRivaroxaban20$24,816
Repatha SureclickEvolocumab13$10,436
Ranolazine ErRanolazine23$1,018
Metoprolol Succinate112$897
Rosuvastatin Calcium35$662
Isosorbide Mononitrate ErIsosorbide Mononitrate56$400
Potassium Chloride28$344
Carvedilol38$309
Hydralazine Hcl30$294
Losartan Potassium36$275
Atorvastatin Calcium57$246
Ezetimibe17$213
Amlodipine Besylate32$192
ClopidogrelClopidogrel Bisulfate11$179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$77$61,61574 claims
Johnson & JohnsonXarelto$101$24,81620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,374 family providers in Kentucky.

Other family in Morehead

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →